Literature DB >> 23721961

The regulation of ApoB metabolism by insulin.

Mary E Haas1, Alan D Attie, Sudha B Biddinger.   

Abstract

The leading cause of death in diabetic patients is cardiovascular disease. Apolipoprotein B (ApoB)-containing lipoprotein particles, which are secreted and cleared by the liver, are essential for the development of atherosclerosis. Insulin plays a key role in the regulation of ApoB. Insulin decreases ApoB secretion by promoting ApoB degradation in the hepatocyte. In parallel, insulin promotes clearance of circulating ApoB particles by the liver via the low-density lipoprotein receptor (LDLR), LDLR-related protein 1 (LRP1), and heparan sulfate proteoglycans (HSPGs). Consequently, the insulin-resistant state of type 2 diabetes (T2D) is associated with increased secretion and decreased clearance of ApoB. Here, we review the mechanisms by which insulin controls the secretion and uptake of ApoB in normal and diabetic livers.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  apolipoprotein B; cardiovascular disease; diabetes; insulin; selective insulin resistance; very low-density lipoprotein (VLDL)

Mesh:

Substances:

Year:  2013        PMID: 23721961      PMCID: PMC3810413          DOI: 10.1016/j.tem.2013.04.001

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  97 in total

Review 1.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

2.  Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice.

Authors:  Emil D Bartels; Morten Lauritsen; Lars B Nielsen
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

3.  Hepatic deficiency of low density lipoprotein receptor-related protein-1 reduces high density lipoprotein secretion and plasma levels in mice.

Authors:  Joshua E Basford; Lauren Wancata; Susanna M Hofmann; R A Gangani D Silva; W Sean Davidson; Philip N Howles; David Y Hui
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

4.  Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice.

Authors:  Ding Ai; Juan M Baez; Hongfeng Jiang; Donna M Conlon; Antonio Hernandez-Ono; Maria Frank-Kamenetsky; Stuart Milstein; Kevin Fitzgerald; Andrew J Murphy; Connie W Woo; Alanna Strong; Henry N Ginsberg; Ira Tabas; Daniel J Rader; Alan R Tall
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 5.  New insight into the pathophysiology of lipid abnormalities in type 2 diabetes.

Authors:  B Vergès
Journal:  Diabetes Metab       Date:  2005-11       Impact factor: 6.041

Review 6.  Sortilin: an unusual suspect in cholesterol metabolism: from GWAS identification to in vivo biochemical analyses, sortilin has been identified as a novel mediator of human lipoprotein metabolism.

Authors:  Joseph B Dubé; Christopher T Johansen; Robert A Hegele
Journal:  Bioessays       Date:  2011-04-04       Impact factor: 4.345

7.  Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.

Authors:  Seongah Han; Chien-Ping Liang; Marit Westerterp; Takafumi Senokuchi; Carrie L Welch; Qizhi Wang; Michihiro Matsumoto; Domenico Accili; Alan R Tall
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

8.  Regulation of hepatic lipogenesis in starved and diabetic animals by thyroid hormone.

Authors:  M C Sugden; D I Watts; C E Marshall
Journal:  Biosci Rep       Date:  1981-10       Impact factor: 3.840

Review 9.  The LDL modification hypothesis of atherogenesis: an update.

Authors:  Daniel Steinberg
Journal:  J Lipid Res       Date:  2008-11-15       Impact factor: 5.922

10.  Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus.

Authors:  A H Kissebah; S Alfarsi; D J Evans; P W Adams
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

View more
  35 in total

Review 1.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

2.  Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33.

Authors:  Ryan M Allen; Tyler J Marquart; Jordan J Jesse; Angel Baldán
Journal:  Circ Res       Date:  2014-04-21       Impact factor: 17.367

3.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

Review 4.  Emerging Targets for Cardiovascular Disease Prevention in Diabetes.

Authors:  Nathan O Stitziel; Jenny E Kanter; Karin E Bornfeldt
Journal:  Trends Mol Med       Date:  2020-05-15       Impact factor: 11.951

Review 5.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

6.  Pinolenic Acid Downregulates Lipid Anabolic Pathway in HepG2 Cells.

Authors:  Ah Ron Lee; Sung Nim Han
Journal:  Lipids       Date:  2016-04-15       Impact factor: 1.880

Review 7.  The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis.

Authors:  Philip L S M Gordts; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

8.  mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion.

Authors:  William J Quinn; Min Wan; Swapnil V Shewale; Rebecca Gelfer; Daniel J Rader; Morris J Birnbaum; Paul M Titchenell
Journal:  J Clin Invest       Date:  2017-10-16       Impact factor: 14.808

Review 9.  Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.

Authors:  Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

10.  An Allosteric Binding Site on Sortilin Regulates the Trafficking of VLDL, PCSK9, and LDLR in Hepatocytes.

Authors:  Robert P Sparks; Andres S Arango; Jermaine L Jenkins; Wayne C Guida; Emad Tajkhorshid; Charles E Sparks; Janet D Sparks; Rutilio A Fratti
Journal:  Biochemistry       Date:  2020-11-05       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.